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Trypanosoma brucei brucei, a causative agent of trypanosomiasis in domestic livestock, and
T. b. rhodesiense and T. b. gambiense, the causative agents of human sleeping sickness, are
tsetse-transmitted flagellated protozoa that multiply extracellularly in infected mammalian
hosts. Variation of the surface glycoprotein (VSG) of T. brucei organisms1 prevents most hosts
from clearing the parasites and leads to chronic and often debilitating infections. The
pathologic consequences of trypanosomiasis caused by T. brucei and other pathogenic
African trypanosomes are manifold, including: anaemia, raised Ig levels, immune complex
disease, progressive destruction of lymphoid organs and other tissues, reduced fertility,
cachexia and neurologic disorders. The severity of these disease symptoms varies among
hosts, which, by this definition, are referred to as more trypano-resistant or more trypano-
susceptible.
Immunity to T. brucei organisms is VSG-specific and is mediated by antibodies that react with
exposed-epitopes on parasite VSG.² It has been observed in model studies that prolonged
infection with African trypanosomes leads to a general inability to mount humoral immune
responses to trypanosomes and third-party antigens.³ A widely held view arising from these
observations is that the level of susceptibility of a given host to infections with African
trypanosomes is likely to reflect the rapidity of development and severity of parasite-induced
immunodepression. In this formulation of the host susceptibility problem, the interaction
between trypanosomes and the humoral limb of the immune system assumes centre stage
and the attention of the audience/investigator is focused on parasite products that drive or
disengage the circuits underlying immune responses.
Recent studies provide reasonable grounds to doubt the above concept.4 An extensive
analysis of plasma-cell responses has been performed in resistant mice, which mount
serologically detectable VSG-specific antibody responses and cause clearance of the first T.
brucei parasitaemic wave, and in susceptible mice, which do not. In both strains of mice
plasma cells arose with the same kinetics, reached similar numbers in all lymphoid organs
examined and synthesized and secreted similar amounts of antibodies of the same Ig classes,
including antibodies specific for exposed VSG-epitopes on the infecting organisms.4
It was shown that the 2.5- to 10-fold higher peak levels of parasitaemia reached in the infected
susceptible, as compared to the resistant, mice could result in the removal by the
trypanosomes of large amounts of antibody. Hence it was inferred that there was less antibody
bound per trypanosome, leading to failure of the susceptible mice to clear parasites from the
bloodstream. VSG-specific antibody absorbed by trypanosomes is endocytosed and degraded
(D. Russo, P. Webster and S. Black, unpublished). Failure to clear trypanosomes from the
bloodstream leads to a prolonged parasitaemic wave, rapid destruction of lymphoid organ
architecture and concomitant loss of ability to mount efficient humoral immune responses.
Accessory studies showed that the higher levels of parasitaemia reached in infected
susceptible, as opposed to resistant, mice correlated with slower parasite differentiation to
committed non-dividing trypanosomes in the bloodstream,5 an event that is probably
controlled by antibody-independent host responses. The rate of parasite differentiation to
committed non-dividing T. brucei in the bloodstream of infected mice can be accelerated by
treatment of mice with Propionibacterium acnes.6 Biological mediators induced by P. acnes
have no direct effect on the parasites in vitro.6 The mediators examined include IL-1, IL-2,
TNF, INF, PGE1, PGE2, PGF2, mitogen-induced mixtures of mediators derived from T cells,
B cells, macrophages and mixed populations of cells (early or late after stimulation), fibroblast
growth factors, endothelial cell growth factors, nerve growth factors, platelet-derived growth
factor, insulin and insulin-like growth factors, tumor-derived growth factors and tumor-
promoting factors6 (S. Black and J. Newson, unpublished). The observations led to the idea
that regulation of trypanosome multiplication and commitment to non-dividing forms might be
mediated by secondary physiological effects of immune mediators that regulated the
availability or nature of host-supplied growth nutrients/growth inhibitors.
Axenic culture systems7 were exploited to identify host-derived macromolecules required for
the multiplication of T. brucei. Two different serodemes of T. brucei were adapted to grow
under axenic culture conditions and the adapted parasites grew equally well in both in vivo
and in vitro environments. No major biochemical adaptations were thus required to transit
between the two environments and hence the in vivo and in vitro T. brucei growth nutrient
requirements were similar.8 The trypanosomes multiplied under axenic culture conditions in
medium supplemented with 10% foetal bovine serum (FBS). In contrast, lipoprotein-depleted-
FBS (LPD-FBS; density 1.25 gm/ml) did not support parasite multiplication unless
supplemented with FBS lipoproteins (density 1.21 gm/ml). High-density lipoproteins (HDL;
density 1.06-1.21 gm/ml) and low-density lipoproteins (LDL; density 1.006-1.06 gm/ml),
prepared by sequential flotation ultracentrifugation, were equally able to supplement LPD-FBS
to support T. brucei multiplication. Chylomicrons (density 0.96 gm/ml) and very low-density
lipoproteins (VLDL; density 0.96-1.006 gm/ml) were unable to support T. brucei multiplication.
Removal of HDL or LDL-lipids by alcohol/ether extraction abrogated the ability of the
lipoproteins to support T. brucei multiplication. Both HDL and LDL from a number of different
species, including cattle, African buffalo, eland, rabbits and rats, were as able as FBS-HDL or
FBS-LDL to support T. brucei multiplication.8 The observations fit well with the published
requirement of bloodstream T. brucei for exogenous lipids9 and suggest the presence of a
lipid scavenging mechanism suited to a parasite with a wide host range.
Foetal bovine serum (FBS), rabbit and rat HDL and LDL were labelled with 125I on the
apolipoprotein content, or with ³H cholesterol, ³H cholesteryl linoleate or ³H dipalmitoyl
phosphatidyl choline, or with combinations of 125I and ³H labels. It was shown that both
culture-adapted T. brucei 8 and T. brucei isolated from the blood of infected mice (including
organisms that had not been culture-adapted) (V. Vandeweerd and S. Black, unpublished)
took up lipoprotein-lipids without talking up or degrading apolipoproteins. Uptake of the
lipoprotein-lipids occurred at 37 °C but not at 0 °C to 4 °C, was saturable and was several
thousand times more efficient than uptake expected to occur by fluid endocytosis. The uptake
process did not discriminate between HDL and LDL, was independent of exogenous divalent
ions and was not influenced by exogenous weak bases (20 mM ammonium chloride, 20 m M
chloroquine8). The uptake mechanism was thus utterly different from receptor-mediated
endocytosis of LDL as practised by mammalian cells. 10
Uptake by T. brucei, X63 mouse myeloma cells and normal mouse spleen cells of lipoprotein-
associated ³H cholesterol occurred to a similar extent. It resulted from desorption of the ³H
cholesterol from the lipoproteins and its diffusion into the plasma membranes of the target
cells. In contrast, uptake of lipoprotein-associated ³H dipalmitoyl phosphatidyl choline and ³H
cholesteryl linoleate differed markedly among the three cell types. Trypansoma brucei
obtained these lipids from both HDL and LDL. X63 obtained the lipids from LDL only and
normal mouse spleen cells did not take up the lipids.8
Uptake by T. brucei of lipoprotein-associated ³H dipalmitoyl phosphatidyl choline was inhibited
by including LPD-FBS in the incubation mixture. The active ingredient in the LPD-FBS was
likely to be albumin. LPD-FBS stimulated rather than inhibited the uptake by T. brucei of
lipoprotein-associated ³H cholesterol linoleate. This observation suggests that lipoprotein-
derived phospholipids and cholesterol esters might enter T. brucei by different processes and
that the phospholipid ³H dipalmitoyl phosphatidyl choline) is free of the carrier lipoprotein prior
to entry into T. brucei.
In contrast, bile acids and conjugated and unconjugated bile salts inhibited the uptake by
culture-adapted and normal bloodstream T. brucei of lipoprotein-associated ³H cholesteryl
linoleate but not lipoprotein-associated ³H dipalmitoyl phosphatidyl choline. Different
cholesterol conversion products had differing efficiencies to inhibit T. brucei lipoprotein-
cholesterol ester uptake. The observed order, derived from inhibition of HDL-associated ³H
cholesterol linoleate uptake using culture-adapted T. brucei as: lithocholic acid >
chenodeoxycholic acid > deoxycholic acid > cholic acid = glycochenodeoxycholic acid >
taurochenodeoxycholic acid (V. Vandeweerd and S. Black, unpublished).
Two possibilities present themselves. The cholesterol conversion products might prevent the
uptake by T. brucei of lipoprotein-associated cholesterol ester by inhibiting cleavage to
cholesterol that can readily diffuse across the cell membrane. Alternatively, the cholesterol
conversion products might compete with an interaction between lipoprotein-associated
cholesterol ester and a T. brucei cholesterol ester binding molecule. To examine these
possibilities, purified lipoproteins were labelled with ³H cholesterol ether ³H cholesterol oleoyl
ether) and incubated with culture-adapted T. brucei in the presence or absence of an
inhibitory concentration of chenodeoxycholic acid. In the absence of the bile acid, the T. brucei
took up ³H cholesterol ether by a process that was similar in all respects to uptake of ³H
cholesterol ester, e.g., uptake occurred only at 37 °C, was saturable, was inhibited by
unlabelled lipoproteins and was enhanced by LPD-FBS. Uptake of the cholesterol ether was
inhibited by the bile acid (Vandeweerd and Black, unpublished). Because cholesterol
esterases are unable to cleave the ether bond11 and because cholesterol ether cannot diffuse
through cell membranes, we conclude that T. brucei have a cholesterol ester/ether binding
molecule that is blocked by cholesterol conversion products.
Both chylomicrons and VLDL contain phospholipids and cholesterol ester yet do not support
T. brucei multiplication and do not inhibit the capacity of LDL or HDL to support T. brucei
multiplication in vitro.
8. It therefore seems possible that size constraints prevent interactions
between the largest lipoprotein molecules and the T. brucei. This conclusion leads to the idea
that lipoprotein/T. brucei interactions occur in the T. brucei flagellar pocket, from which the
larger lipoproteins might be excluded. Alternatively, cholesterol esters and phospholipids might
be sequestered in chylomicrons and VLDL in such a way that they cannot interact with T.
brucei organisms. As a preliminary step to distinguishing between these possibilities, it is of
some importance to define the maximum size of molecules that can enter the T. brucei
flagellar pocket.
Uptake by T. brucei of HDL-associated ³H cholesteryl linoleate is inhibited by including
puromycin or cycloheximide (20 m g/ml medium) in the incubation mixture. In contrast, uptake
by T. brucei of HDL-associated ³H dipalmitoyl phosphatidyl choline is not inhibited by including
puromycin or cycloheximide in the incubation mixture. We therefore consider it likely that
uptake of the 3H cholesteryl linoleate is mediated by binding to a protein, whereas uptake of
3H dipalmitoyl phosphatidyl choline is not. Based on these observations and the ability of LPD-
FBS (albumin) to prevent uptake by T. brucei of lipoprotein-associated ³H dipalmitoyl
phosphatidyl choline, we speculate that the ³H phospholipid is released from the lipoprotein
particle by a process that does not require protein synthesis by the parasite and thereafter
diffuses into the parasite membrane. It is tempting to suggest that release of the lipoprotein-
associated phospholipid occurs in the T. brucei flagellar pocket as a result of mechanical
disruption of the lipoprotein particle. The uptake by T. brucei of lipoprotein-associated
cholesterol occurs as a result of simple desorption; uptake of phospholipid possibly occurs by
mechanically induced release and diffusion. Uptake by T. brucei of lipoprotein-associated
cholesterol ester may therefore be the only component of the parasite lipid scavenging
mechanism amenable to specific chemotherapeutic or immunological attack.
Concentrations of bile acids (5 to 15 m M), and conjugated and unconjugated bile salts (50 to
100 m M), which inhibit uptake by T. brucei of lipoprotein-associated cholesterol ester/ether in
the absence of LPD-FBS, are close to toxic concentrations. Although the inclusion of LPD-
FBS in the incubation mixture reduces the short-term toxicity of cholesterol conversion
products, it does not completely abrogate their effects. Concentrations of bile acids (100 m M)
can be chosen that prevent multiplication of T. brucei in long-term cultures supplemented with
10% FBS. Because conjugated bile salts and bile acids are found in normal plasma, it is an
attractive idea that these molecules might have a role to play in protection against African
trypanosomes. Clearly, quantitative data are required on the bile acid, and conjugated and
unconjugated bile salt concentrations in the plasma and interstitial fluids of normal and
infected trypano-susceptible and trypano-resistant hosts. Equally clearly, quantitative data are
required on the sensitivity of different trypanosome clones, serodemes and species to the toxic
effects of cholesterol conversion products in the presence or absence of blood.
We hope that the above overview will stimulate further studies on trypanosome nutrient
uptake, on the host/trypanosome interface as manifested in the T. brucei flagellar pocket and
on the mechanisms used by infected hosts to control parasite growth.
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